2013
Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park JE, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, Paltiel AD. Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. PLOS ONE 2013, 8: e84173. PMID: 24367639, PMCID: PMC3867470, DOI: 10.1371/journal.pone.0084173.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioQuality-adjusted life monthsRoutine HIVHIV test acceptanceRoutine HIV screeningAge 43 yearsCells/μLSecondary HIV transmissionHigh-risk groupHigh-risk populationRoutine screening programQuality-adjusted survivalCost-effectiveness ratioCD4 countHIV screeningClinical outcomesHIV prevalenceHIV transmissionFrequent screeningClinical impactNational HIVScreening programHigh incidenceHIV
2010
Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLOS ONE 2010, 5: e13132. PMID: 20976112, PMCID: PMC2956760, DOI: 10.1371/journal.pone.0013132.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsCost-effectiveness ratioQuality-adjusted life yearsGeneral populationRoutine HIVHIV prevalenceFrequent screeningLife expectancyAnnual HIV incidenceRoutine HIV screeningUndiagnosed HIV prevalenceHigh-risk groupHIV testing behaviorsInjection drug usersFrench general populationEpidemiology of infectionHIV screeningVoluntary HIVHIV infectionHIV testingAnnual screeningHIV incidenceMean ageHIV screenClinical impact